Skip to content
Screener

MBX Biosciences, Inc. MBX Retained Earnings

Retained Earnings at other companies

Eli Lilly logo
Eli LillyLLY
$31.89B+83.5%
Amgen logo
AmgenAMGN
-$22.28B+13.4%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$1.01B-88.5%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$836.13M-22.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$3.99B-22.1%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$1.18B-40.7%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$3.19B+719%
Enterprise value$3.15B+798%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 9:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210593
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized and zero issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value, 500,000,000 shares authorized and 47,570,464 issued and outstanding as of March 31, 2026 and 500,000,000 shares authorized and 44,927,953 issued and outstanding as of December 31, 202566
Additional paid-in-capital686,349593,407
Accumulated deficit(247,993)(224,476)
Accumulated other comprehensive (loss) income(606)286
Total stockholders’ equity437,756369,223
Total liabilities and stockholders’ equity$452,701$385,144

Item 1. Financial Statements.

FAQ

What is MBX Biosciences, Inc.'s retained earnings?
MBX Biosciences, Inc. (MBX) reported retained earnings of -$247.99M in Q1 2026.
How has MBX Biosciences, Inc.'s retained earnings changed year-over-year?
MBX Biosciences, Inc.'s retained earnings decreased by 53.7% year-over-year, from -$161.39M to -$247.99M.
What is the long-term trend for MBX Biosciences, Inc.'s retained earnings?
Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s retained earnings has grown at a 72.3% compound annual growth rate (CAGR), from -$75.58M to -$224.48M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about MBX Biosciences, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude